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Abstract
Novel oral anticoagulants (NOACs), which include 
direct thrombin inhibitor (dabigatran) and direct factor 
Xa inhibitors (rivaroxaban, apixaban and edoxaban), 
are gaining popularity in the prevention of embolic 
stroke in non-valvular atrial fibrillation as well as in the 
prevention and treatment of venous thromboembolism. 
However, similar to traditional anticoagulants, NOACs 
have the side effects of bleeding, including gastro-
intestinal bleeding (GIB). Results from both randomized 
clinical trials and observations studies suggest that 
high-dose dabigatran (150 mg b.i.d), rivaroxaban and 
high-dose edoxaban (60 mg daily) are associated with 
a higher risk of GIB compared with warfarin. Other risk 
factors of NOAC-related GIB include concomitant use 
of ulcerogenic agents, older age, renal impairment, 
Helicobacter pylori  infection and a past history of GIB. 
Prevention of NOAC-related GIB includes proper patient 
selection, using a lower dose of certain NOACs and in 
patients with renal impairment, correction of modifiable 
risk factors, and prescription of gastroprotective agents. 
Overt GIB can be managed by withholding NOACs 
followed by delayed endoscopic treatment. In severe 
bleeding, additional measures include administration 
of activated charcoal, use of specific reversal agents 
such as idarucizumab for dabigatran and andexanent 
alfa for factor Xa inhibitors, and urgent endoscopic 
management. 
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treatment of thromboembolism, novel oral anticoa-
gulants (NOACs) are still associated with bleeding 
complications including gastrointestinal bleeding (GIB). 
Physicians should exercise caution in the prescription 
of these drugs with careful review of the indications 
and appropriate dosage, as well as balancing the risks 
and benefits. Nonetheless, patients perceived to have 
an increased risk of GIB should not be precluded from 
taking NOACs, if they are also at a high risk of stroke. 
Instead, physicians should recognize the risk factors 
associated with NOAC-related GIB in order to undertake 
preventive measures to reduce the risk of GIB. 
Cheung KS, Leung WK. Gastrointestinal bleeding in patients 
on novel oral anticoagulants: Risk, prevention and management. 
World J Gastroenterol 2017; 23(11): 1954-1963  Available from: 
URL: http://www.wjgnet.com/1007-9327/full/v23/i11/1954.htm 
DOI: http://dx.doi.org/10.3748/wjg.v23.i11.1954
INTRODUCTION
Novel oral anticoagulants (NOACs) include direct 
thrombin inhibitor (dabigatran) and direct factor Xa 
inhibitors (rivaroxaban, apixaban and edoxaban) 
are increasingly favored over conventional oral anti­
coagulants such as warfarin. NOACs are often used 
in the prevention of embolic stroke in non­valvular 
atrial fibrillation (AF) as well as in the prevention 
and treatment of venous thromboembolism (VTE). 
Compared with warfarin, NOACs have rapid onset 
and offset of action, predictable pharmacodynamics 
obviating regular therapeutic monitoring, and fewer 
food­drug or drug­drug interactions[1]. Although NOACs 
have been shown to have a favorable safety profile 
from multiple meta­analyses and phase IV studies, 
the risk of bleeding, particularly gastrointestinal 
bleeding (GIB), is still a concern in high­risk patients. 
This review will discuss the risk of GIB related to 
commonly prescribed NOACs with special focus on 
the dosing of different indications and in patients 
with impaired renal function, differences in bleeding 
risk between randomized clinical trials (RCTs) and 
observational studies, risk factors for GIB, prevention 
and management strategies. 
NOMENCLATURE FOR ORAL 
ANTICOAGULANTS
Apart from “NOACs”, other terms that have been used 
to describe these new oral anticoagulants include direct 
oral anticoagulants (DOACs) and target­specific oral 
anticoagulants. There are also calls to restrict the term 
“NOACs” to “non­vitamin K oral anticoagulants” instead 
of “novel oral anticoagulants”[2], as this terminology is 
well established in the medical literature. Recently, it 
has also been advocated that term “DOACs” should be 
adopted as the name implies similar pharmacological 
actions of this class of oral anticoagulants that inhibit 
a single target[3]. In this review, we use the term 
“NOACs” to refer to novel oral anticoagulants inclusive 
of dabigatran, rivaroxaban, apixaban and edoxaban. 
PHARMACOLOGY OF NOAC 
The characteristics and dosing of different NOACs are 
summarized in Tables 1 and 2. Dabigatran directly 
inhibits thrombin activity in a reversible manner. It 
is administered as a prodrug known as dabigatran 
etexilate and after absorption in the proximal small 
bowel, dabigatran etexilate is cleaved by serum 
and hepatic esterases to the active form[4]. The bio­
availability of dabigatran etexilate is 7% with the 
majority of non­absorbed drug being excreted in the 
stool. Absorbed drug is mainly excreted unchanged by 
the kidneys. The half­life of dabigatran ranges from 
9 to 17 h, depending on individuals’ age and renal 
function. Dabigatran can be administered at a dose of 
150 mg b.i.d or 110 mg b.i.d, and 75 mg b.i.d in the 
presence of renal insufficiency [creatinine clearance 
(CrCl) < 50 mL/min][5]. The drug is contraindicated 
in patients with severe renal impairment (CrCl < 30 
mL/min) or advanced liver disease[6]. 
Rivaroxaban is a direct inhibitor of factor Xa, which 
reduces thrombin production. It has a bioavailability of 
66%[7,8]. One­third of the absorbed drug is excreted by 
the kidney and two­thirds is metabolized by the liver 
into inactive forms. The half­life ranges from 6 to 13 
h[8]. Rivaroxaban is administered at a dose of 20 mg 
daily, and 15 mg daily if the CrCl is < 50 mL/min[5]. The 
drug is also contraindicated in severe renal impairment 
(CrCl < 15 mL/min) or advanced liver disease[6]. 
Similar to rivaroxaban, apixaban directly inhibits 
factor Xa. It has a bioavailability of 50%[9]. Around 25% 
of the absorbed drug is excreted by the kidney with a 
half­life of around 12 h. Apixaban is administered at a 
dose of 5 mg b.i.d, and 2.5 mg b.i.d if patients has at 
least 2 of the following features: age 80 years or older, 
body weight 60 kg or less, or serum creatinine 1.5 
mg/dL or more[5]. 
Edoxaban is also a direct factor Xa inhbitior, with 
a bioavailability of 60% and a half­life of around 12 
h. Renal clearance accounts for 50% of the total 
clearance[6]. Edoxaban can be administered at a dose 
of 60 mg daily, and 30 mg daily if the CrCl is < 50 
mL/min or body weight is less than 60 kg. The drug is 
contraindicated in severe renal impairment (CrCl < 15 
mL/min) and advanced liver disease. Of note, serum 
levels of NOACs can be increased by potent inhibitors 
of p­glycoprotein and CYP3A4 (e.g., azole antifungal 
agents, protease inhibitors), while serum levels can 
be decreased by strong inducers of p­glycoprotein and 
CYP3A4 (e.g., rifampicin)[10].
MECHANISMS OF NOAC-RELATED GIB 
There are several mechanisms by which NOAC causes 
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GIB[1] (Figure 1). The anticoagulant effect can be 
local and/or systematic, and NOACs may inhibit GI 
mucosal healing. In addition, the tartaric acid in da­
bigatran etexilate is postulated to cause direct caus­
tic injury. When compared with warfarin, dabigatran 
and rivaroxaban are associated with an increased 
risk of GIB only, but have not been demonstrated to 
increase bleeding in other organs including intracranial 
hemorrhage[1,10]. Of note, the sites of GIB differ for 
individual NOACs. In contrast to the usual pattern 
observed with warfarin, aspirin or non­steroidal anti­
inflammatory drugs (NSAIDs) where upper GIB 
predominates[11], lower GIB accounted for 53% of major 
GIB seen in dabigatran users in the RE­LY trial[12]. This 
has been hypothesized to be related to the incomplete 
absorption of the active NOACs in the upper GI tract 
with resulting increasing availability of dabigatran to the 
lower GI tract which exert topical effect on the mucosa 
leading to bleeding, especially in the presence of pre­
existing lesions like angiodysplasias and erosions[4]. On 
the other hand, the bioavailability of warfarin is more 
than 95%, and non­absorbed warfarin does not have 
any topical effect[1,10]. Notably, upper GIB appeared to 
be more common than lower GIB among rivaroxaban 
users (76 % vs 24%)[13], while the risks of upper and 
lower GIB were comparable with high­dose edoxaban 
(60 mg daily)[6,14]. 
The dosing of NOACs may also affect the risk of 
GIB[1,10]. Both rivaroxaban and apixaban are factor 
Xa inhibitors, administered in active form, and have 
similar bioavailability. However, these two agents differ 
in the risk of GIB, which may be related to the higher 
peak level of once­daily dosing of rivaroxaban than 
the twice­daily dosing of apixaban. Similarly, the once­
daily dosing of rivaroxaban may also account for the 
higher GIB risk observed in the head­to­head study of 
rivaroxaban and dabigatran[15]. 
RISK OF NOAC-RELATED GIB IN RCTS
Holster et al[16] summarized the risk of GIB associated 
with NOACs in a recent meta­analysis, which included 
17 RCTs with a total of 75081 patients who received 
either NOACs or standard care (defined as either 
low­molecular­weight heparin, vitamin K antagonist, 
antiplatelet therapy or placebo). During a follow­up 
period ranging from 3 wk to 31 mo, there was a 1.5% 
GIB event, with 89% being major GIB (defined as 
GIB leading to a decrease in hemoglobin ≥ 2 g/dL 
within 24 h, a transfusion of ≥ 2 units of packed red 
cells, necessitating intervention including surgery, or 
fatal bleeding). The number needed to harm was 500. 
Overall, there was an increased risk of GIB among 
NOAC users, compared with standard care [pooled 
odds ratio (OR) 1.45], though significant heterogeneity 
existed regarding drug choices and the indications of 
anticoagulation. 
Among different NOACs, both dabigatran and 
rivaroxaban were associated with a higher risk of GIB 
(OR 1.58 and 1.48, respectively), but not apixaban 
and edoxaban. However, since there are still no direct 
head­to­head comparisons of GIB risks among various 
NOACs in RCTs, it is difficult to conclude which drug 
has the lowest GIB risk. As patient characteristics 
differed across studies, indirect comparisons can be 
misleading[17]. 
For various indications of NOACs, the highest risk of 
GIB was seen in patients with acute coronary syndrome 
(OR 5.21), in whom NOACs were co­prescribed with 
antiplatelet agents. Patients prescribed NOACs for 
deep vein thrombosis and pulmonary embolism also 
had an increased risk of bleeding (OR 1.59). However, 
the GIB risk was not significantly increased in patients 
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Table 1  Characteristics of different novel oral anticoagulants 
Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of action Anti-thrombin Anti-factor Xa Anti-factor Xa Anti-factor Xa
Bioavailability 7% 66% 50% 60%
Tmax (h) 1.5 2.5   3 1-5
T½ (h) 9-17 6-13 12 12
Dosing b.i.d once daily b.i.d once daily
Renal excretion High Moderate Moderate Moderate
Hepatic metabolism Low Moderate Moderate Moderate
Reversal agents Idarucizumab1 Andexanet alfa Andexanet alfa Andexanet alfa
Aripazine Aripazine Aripazine Aripazine
1Idarucizumab is the only FDA-approved specific reversal agent currently. Tmax: Time to peak plasma level; T½: Half-life; GIB: Gastrointestinal bleeding. 
Systemic anticoagulant effect
Topical effect
1. Incomplete absorption 
    (topical anticoagulant effect)
2. Direct caustic effect 
    (tartaric acid in dabigatran)
3. Inhibition of mucosal healing
Figure 1  Pathogenesis of novel oral anticoagulant-related gastrointestinal 
bleeding. NOAC: Novel oral anticoagulant; GIB: Gastrointestinal bleeding.
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usually receive NOACs for a short, finite period (few 
weeks only)[18]. It has also been shown that among 
patients receiving dabigatran, only the higher dose 
(150 mg b.i.d) was associated with a higher GIB risk 
when compared with warfarin, indicating a dose­related 
effect[12,19­22]. The risk of GIB was also increased with 
high­dose edoxaban of 60 mg daily (HR 1.23), but was 
reduced with low­dose edoxaban of 30 mg daily (HR 
0.89)[14]. However, subsequent systematic reviews and 
receiving NOACs for prevention of VTE after orthopedic 
surgery and in medically ill patients. Although there 
was no significant increase in the overall risk of GIB 
among all patients receiving NOACs for AF, subgroup 
analysis showed an increase in risk among dabigatran 
and rivaroxaban users. The increased GIB risk in AF (but 
not with thromboprophylaxis after orthopedic surgery) 
among dabigatran and rivaroxaban users is likely 
explained by the duration effect, as orthopedic patients 
Table 2  Dosing of different novel oral anticoagulants according to indications and renal function
Dabigatran Rivaroxaban Apixaban Edoxaban
Non-valvular AF
   United States 150mg b.i.d 20 mg daily 5 mg b.i.d 60 mg daily
75 mg b.i.d if CrCl 15-30 mL/
min
15 mg daily if CrCl 15-50 mL/
min
2.5 mg b.i.d if Cr 15-29 mL/min 
OR two out of the following:
30 mg daily if CrCl 15-50 mL/
min
age ≥ 80 years, BW ≤ 60 kg, Cr 
≥ 1.5 mg/dL
Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 25 mL/min or 
Cr > 2.5 mg/dL
Avoid if CrCl < 15 mL/min
   Europe 150 mg b.i.d 20 mg daily 5 mg b.i.d 60 mg daily
110 mg b.i.d if age ≥ 80 years - 2.5 mg b.i.d if Cr 15-29 mL/min 
OR two out of the following:
30 mg daily if one out of the 
following: CrCl 15-50 mL/min, 
BW ≤ 60 kg, concomitant use of 
p-gp inhibitors
(may consider 110 mg b.i.d also 
if increased risk of bleeding)
age ≥ 80 years, BW ≤ 60 kg, 
Cr ≥ 1.5 mg/dL
Avoid if CrCl < 30 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min
Postoperative DVT / PE thromboprophylaxis (hip or knee replacement)
   United States Initial dose of 110 mg 1-4 h after 
operation, then 220 mg daily
Initial dose of 10 mg 6-10 h after 
operation, then 10 mg daily
Initial dose of 2.5 mg 12-24 h 
after operation, then 2.5 mg b.i.d
-
- - - -
Avoid if CrCl < 30 Avoid if CrCl < 30 mL/min Avoid if CrCl < 30 mL/min -
   Europe Initial dose of 110 mg 1-4 h after 
operation, then 220 mg daily
Initial dose of 10 mg 6-10 h after 
operation, then 10 mg daily
Initial dose of 2.5 mg 12-24 h 
after operation, then 2.5 mg b.i.d
60 mg daily after 5 d of initial 
therapy with a parenteral 
anticoagulant
Initial dose of 75 mg 1-4 h after 
operation, then 150 mg daily if 
CrCl 30-50 mL/min
- - 30 mg daily after 5 d of initial 
therapy with a parenteral 
anticoagulant if one out of the 
following: CrCl 15-50 mL/min, 
BW ≤ 60 kg, concomitant use of 
p-gp inhibitors
Avoid if CrCl < 30 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min
Treatment and prevention of recurrent DVT/PE
   United States 150 mg b.i.d after 5-10 d of 
initial therapy with a parenteral 
anticoagulant
15 mg b.i.d for 3 wk, then 20 mg 
daily
10 mg b.i.d for 1 wk, then 5 mg 
b.i.d
60 mg daily after 5-10 d of 
initial therapy with a parenteral 
anticoagulant
- - - 30 mg daily after 5-10 d of 
initial therapy with a parenteral 
anticoagulant if one out of the 
following: CrCl 15-50 mL/min, 
BW ≤ 60 kg, concomitant use of 
p-gp inhibitors
Avoid if CrCl < 30 mL/min Avoid if CrCl < 30 mL/min Avoid if CrCl < 25 mL/min 
or Cr > 2.5 mg/dL
Avoid if CrCl < 15 mL/min
   Europe 150 mg b.i.d after 5 d of initial 
therapy with a parenteral 
anticoagulant
15 mg b.i.d for 3 wk, then 20 mg 
daily
10 mg b.i.d for 1 wk, then 5 mg 
b.i.d
60 mg daily after 5 d of initial 
therapy with a parenteral 
anticoagulant
110 mg b.i.d after 5 d of initial 
therapy with a parenteral 
anticoagulant if age ≥ 80 years
- - 30 mg daily after 5 d of initial 
therapy with a parenteral 
anticoagulant if one out of the 
following: CrCl 15-50 mL/min, 
BW ≤ 60 kg, concomitant use of 
p-gp inhibitors
(may consider 110 mg b.i.d also 
if increased risk of bleeding)
Avoid if CrCl < 30 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min Avoid if CrCl < 15 mL/min
NOACs: Novel oral anticoagulants; AF: Atrial fibrillation; CrCl: Creatinine clearance; BW: Body weight; Cr: Creatinine; DVT: Deep vein thrombosis; PE: 
Pulmonary embolism; p-gp inhibitors: p-glycoprotein inhibitors.
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meta­analyses which included more trials with different 
inclusion and exclusion criteria yielded conflicting 
results, showing either no or only a marginal increase in 
the risk of GIB[23­29].
RISK OF NOAC-RELATED GIB IN 
OBSERVATIONAL STUDIES 
As most RCTs adopted stringent inclusion and exclusion 
criteria to enroll patients with relatively low risk of GIB, 
the results may not be generalizable to the general 
population. It was initially estimated that when NOACs 
were marketed, the risk of bleeding could be increased 
up to 15­fold as a result of prescription of these drugs 
to patients with higher risk of GIB[30]. In addition, RCTs 
that separately reported on GIB were usually limited to 
major GIB only, leading to an underestimation of the 
risk of all GIB[16].
To determine the association between NOACs and 
GIB in real­life settings, a recent meta­analysis[19] 
included 8 cohort studies with a total of 117339 NOAC 
users of either dabigatran or rivaroxaban. The pooled 
incidence rates of GIB were 4.5 per 100 patient­years 
and 7.18 per 100 patient­years for patients receiving 
dabigatran and rivaroxaban, respectively. Compared 
with warfarin, dabigatran was associated with an 
increased risk of GIB [relative risk (RR) 1.21], but 
rivaroxaban did not confer a significant increase in 
risk. However, one could not conclude that rivaroxaban 
had a lower GIB risk compared with dabigatran, 
as the non­significant association with GIB risk for 
rivaroxaban may be related to fewer observational 
studies, a shorter follow­up duration and an overall 
younger age of rivaroxaban users. In fact, in a recent 
head­to­head comparative observational study that 
recruited 118891 patients with non­valvular AF who 
were aged 65 years or older[15], rivaroxaban was 
found to be associated with a higher risk of major GIB 
compared with dabigatran (150 mg b.i.d) [hazard 
ratio (HR) 1.40]. Although the differences in baseline 
characteristics were adjusted by propensity scores in 
this study, the result should still be interpreted with 
caution due to the possibility of residual confounding 
by unmeasured factors. 
Contrary to previous postulation[30], the risk of 
GIB was slightly lower in observational studies when 
compared with that reported in RCTs[16]. Several factors 
may account for this finding. Firstly, RCTs recruited 
older patients who had higher risk of stroke. In the 
four landmark phase III RCTs (RE­LY, ROCKET­AF, 
AIRSOTLE, ENGAGE AF­TIMI 48 trials)[14,20,31,32], the 
mean or median age of NOAC users was 70 years or 
above, while subjects from 5 studies included in the 
meta­analysis of cohort studies had a mean age below 
70 years[33­37]. Secondly, patients from observational 
studies had fewer comorbidities, as reflected by a 
lower CHADS2 (congestive heart failure, hypertension, 
age of 75 years or above, diabetes mellitus, history of 
stroke, transient ischemic attack or thromboembolism) 
score[19]. Thirdly, physicians may avoid prescribing 
NOACs to high­risk patients in real­life practice.
One major concern about the meta­analysis of 
observational studies is that the results may be biased 
due to confounding factors. Nonetheless, major con­
founding factors including age, use of gastroprotective 
agents and ulcerogenic agents (including antiplatelet 
agents, NSAIDs, steroid and selective serotonin 
reuptake inhibitors), as well as indications of anti­
coagulation were evaluated by subgroup and sensitivity 
analysis. As for apixaban and edoxaban, observational 
studies comparing their risk of GIB with that of warfarin 
are currently lacking. 
PREVENTION OF NOAC-RELATED GIB
Factors associated with the NOAC­related GIB are 
summarized in Table 3. Older age (≥ 75 years) was 
associated with an increased risk of NOAC­related GIB. 
Among patients receiving dabigatran, there is a 2.5­fold 
increase in risk of GIB[12,34,36,38]. A greater risk of major 
GIB was also observed in older patients receiving 
rivaroxaban[34,39]. As elimination of NOACs depends on 
Risk factors Definition
   Higher dose of dabigatran and edoxaban Dabigatran: a dose of 150 mg b.i.d
Edoxaban: a dose of 60 mg daily
   Concomitant use of ulcerogenic agents Antiplatelet agents, NSAIDs or steroid
   Older age Age ≥ 75 years
   Renal impairment Creatinine clearance < 50 mL/min
   Prior history of peptic ulcers or GIB 
   Helicobacter pylori infection
   Pre-existing GI tract lesions Examples like diverticulosis, angiodysplasias
   Ethnicity Western population
   HAS-BLED score Score of ≥ 3
Protective factors Definition
   Gastroprotective agents Proton pump inhibitors or histamine H2-receptor antagonists
NOAC: Novel oral anticoagulant; GIB: Gastrointestinal bleeding; NSAIDs: Non-steroidal anti-inflammatory drugs.
Table 3  Risk factors for novel oral anticoagulant-related gastrointestinal bleeding
Cheung KS et al . GI bleeding in patients on NOACs
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renal excretion, patients with impaired renal function 
are more likely to have drug accumulation and hence 
higher bleeding risk[10]. A prior history of peptic 
ulcer disease or GIB was associated with a 2.3­fold 
increased risk of GIB[38]. Concomitant antiplatelet 
therapy is also a well­recognized risk factor[12,16,38,40]. 
For example, among dabigatran users, concomitant 
antiplatelet use was associated with a 30% to 50% 
higher risk of GIB[12,38]. 
Ethnicity was another risk factor. Chinese patients 
receiving dabigatran were observed to have a higher 
incidence rate of GIB (4.2 per 100 person­years)[38], 
compared with the western population (1.2 to 1.5 
per 100 person­years in Denmark and 0.6 to 3.4 per 
100 person­years in the United States)[22,41]. Genetic 
factors, particularly factor V­Leiden mutation which is 
exceedingly rare in the Asians, may account for this 
difference[42­44]. 
The HAS­BLED score (hypertension, abnormal liver/
renal function, history of stroke, bleeding tendency, 
labile INRs, elderly aged ≥ 65 years, drug/alcohol 
use) was initially derived to predict bleeding risk of 
warfarin in patients with AF (Table 4)[45]. A score of ≥ 
3 is considered high­risk, with a score of 3 conferring 
a risk of 3.74 bleeding events per 100 patient­
years[45,46]. However, it should be acknowledged that 
patients with an increased risk of thromboembolism 
usually have one or more of the comorbidities included 
in the HAS­BLED score, which predispose them to 
bleeding. Other risk factors for GIB [e.g., Helicobacter 
pylori (HP) infection, colonic diverticulosis, or presence 
of angiodysplasias] should also be considered in the 
decision making when prescribing NOACs[47]. Concurrent 
use of antiplatelet agents and NSAIDs also increases 
the bleeding risk and should factor into the decision 
making.
Co­administration of gastroprotective agents [either 
proton pump inhibitors (PPIs) or histamine H2­receptor 
antagonists (H2RAs)] was found to be associated with 
a 50% reduction in the risk of GIB[38]. This protective 
effect seems to be confined to the upper GI tract 
among those who had history of peptic ulcer disease or 
GIB. PPIs offered a slightly better protective effect than 
H2RAs, with the largest effect seen in patients using 
both PPIs and H2RAs (85% reduction in the risk of 
GIB)[38]. The protective effect may be mediated by the 
reduction of bleeding from pre­existing peptic ulcers. In 
addition, acid suppression may reduce the absorption 
of dabigatran[20,48]. While the impact of gastroprotective 
agents is strong for dabigatran­related GIB, the effect 
appears to be modest for rivaroxaban[19].
Prevention of GIB relies on first reviewing the 
indications of NOACs and avoiding NOACs in patients 
with contraindications[49], including renal impairment 
(CrCl less than 30 mL/min for dabigatran and CrCl less 
than 15 mL/min for other NOACs), and advanced liver 
disease with coagulopathy. Other preventive measures 
include the use of appropriate dosage with reference to 
the CrCl, institution of renal protective measures (e.g., 
avoiding NSAIDs and herbs), correction of modifiable 
risk factors (e.g., HP eradication, alcohol abstinence, 
avoidance of co­administration of antiplatelet agents 
or NSAIDs). For patients identified to be at high risk 
for GIB (e.g., HAS­BLED score ≥ 3, history of previous 
GIB), prescription of gastroprotective agents[1,10,47] and 
use of apixaban or low­dose dabigatran (110 mg b.i.d) 
are recommended[6,50]. However, it is also important 
to note that lower dose of NOACs is less efficacious in 
stroke prevention[26]. For the same reason, the use of 
HAS-BLED score is meant to “flag up” patients at high 
risk for GIB rather than to withold anticoagulation[51]. 
For those who have experienced GIB while on warfarin, 
dabigatran (150 mg b.i.d) or rivaoxaban, reducing 
the dose of dabigatran to 110 mg b.i.d or switching 
to apixaban may be considered[1,50]. Screening and 
surveillance colonoscopy has been advocated to 
detect occult tumors before initiation of NOACs, hence 
reducing the incidence of tumor­associated GIB[6,52]. 
This practice, however, is not the standard of care 
recommended by the American Heart Association and 
American Stroke Association (AHA/ASA) or the CHEST 
guidelines. Interestingly, NOACs may lead to an earlier 
diagnosis of GI tract malignancies as they may provoke 
bleeding of these lesions[52].
Table 4  Components of HAS-BLED bleeding risk score
Clinical characteristics Definition Points
Hypertension Systolic blood pressure > 160 mmHg 1
Abnormal liver or renal function Chronic liver disease (e.g., cirrhosis) or biochemical evidence of significantly impaired liver 
function (e.g., bilirubin > 2 times the ULN plus one or more liver enzymes > 3 times the ULN
1 or 2
Chronic dialysis, renal transplantation, or serum creatinine ≥ 200 micromol/L
Stroke Previous history of stroke 1
Bleeding tendency or predisposition Bleeding disorder or previous bleeding episode requiring hospitalization or transfusion 1
Labile INRs Labile INRs in patients taking warfarin 1
(failure to maintain a therapeutic range at least 60% of the time)
Elderly Age > 65 years 1
Drugs Concomitant antiplatelet agents or NSAIDs 1 or 2
Excessive alcohol use (≥ 8 units per week)
Maximum score is 9. ULN: Upper limit of normal; INR: International normalized ratio; NSAIDs: Non-steroidal anti-inflammatory drugs.
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MANAGEMENT OF OVERT GIB 
Specific management of patients taking NOACs who 
present with overt, non­major GIB involves cessation 
of the drug and endoscopic management[1,10,49]. Owing 
to the short half­life, cessation of drug will lead to a 
rapid return of the coagulant function within 12­24 
h and near complete recovery after five half­lives in 
patients with normal renal function[5,10]. In the case 
of severe bleeding and/or hemodynamic instability, 
activated charcoal, hemodialysis/hemoperfusion and 
reversing anticoagulation can be considered. Activated 
charcoal can be given to reduce intestinal absorption 
of residual drug if the last dose of the NOAC is taken 
within 2 h. This potential benefit needs to be weighed 
against subsequent impairment of endoscopic visua­
lization[53]. Hemodialysis or hemoperfusion may also be 
considered for dabigatran in the case of life­threatening 
GIB or renal failure[54], but not for direct factor Xa 
inhibitors as they are highly protein­bound[1]. 
Non­specific reversal agents include prothrombin 
complex concentrates (PCCs) (either weight­based 
3­factor or 4­factor PCCs), activated PCCs and 
recombinant factor VIIa (rFVIIa). However, well­
designed clinical trials are not available to prove 
their efficacy, and their use was also infrequent in 
the phase III trials and observational studies[5,49]. 
Moreover, their use has been associated with a risk of 
thromboembolism[55­57], although it has been shown 
in a recent study that 4­factor PCCs actually had 
a similar safety profile compared with fresh frozen 
plasma in terms of thromboembolic events (around 
7%) and deaths[58]. Given the uncertain efficacy and 
the potential risk of thromboembolism, these agents 
should only be considered in the following situations: 
life­threatening GIB, ongoing bleeding despite standard 
measures, or delayed clearance of NOACs in patients 
with renal failure[49]. Anti-fibrinolytic agents (tranexamic 
acid) have been used in the management of NOAC­
related GIB, but the experience is still limited[49,59]. FFP 
and cryoprecipitate are not effective in reversing the 
anticoagulant effect[49]. 
Specific reversal agents have also been developed 
recently. Idarucizumab, a humanized monoclonal 
antibody fragment (Fab) against dabigatran, is shown 
to be able to completely reverse anticoagulation in 
around 90% of patients[60], and has been approved 
in the United Sates. Andexanet alfa is a recombinant 
modified human factor Xa decoy protein which 
binds to the factor Xa inhibitors, and therefore is a 
universal factor Xa reversal agent[49]. It has been 
shown to substantially reverse anti­factor Xa activity, 
with hemostasis achieved in around 80% of patients 
presenting with acute major bleeding[61]. Aripazine 
is a cationic small molecule that can prevent NOACs 
(including dabigatran and factor Xa inhibitors) from 
binding with their targets through non­covalent 
binding and charge­charge interaction[62]. It is still in 
the developmental phase, but has shown promising 
results. However, these agents are also associated 
with thromboembolic risks. For instance, around 5% 
and 18% developed thromboembolism after receiving 
idarucizumab and andexanet alfa, respectively[60,61].
The timing of endoscopy depends on the severity 
of GIB and hemodynamic status of the patients. In 
patients with mild GIB, endoscopic evaluation can be 
deferred for 12­24 h[10,63]. Advantages of this delayed 
approach are increased effectiveness of endoscopic 
intervention as the drug effects have worn off, increased 
safety in a non­emergency setting, and improved 
endoscopic visualization due to attenuation/cessation 
of bleeding and better colonic cleansing. On the other 
hand, if patients present with severe GIB or are hemo­
dynamically unstable, emergency endoscopy should 
be performed promptly after resuscitation. Radiological 
and/or surgical interventions will be the last resort if 
repeated endoscopic management fails. 
CONCLUSION
Compared with warfarin, there is a higher risk of GIB 
for high­dose dabigatran (150 mg b.i.d), rivaroxaban 
and high­dose edoxaban (60 mg daily). Reviewing 
the indications of NOACs and prescribing a particular 
NOAC on an individual basis are therefore of utmost 
importance. In addition, physicians should be aware 
of the risk factors for NOAC­related GIB and adopt 
preventive measures accordingly. In the majority of 
cases, overt GIB can be handled by withholding NOACs 
combined with delayed endoscopic treatment.
REFERENCES
1 Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding 
with the new oral anticoagulants--defining the issues and the 
management strategies. Thromb Haemost 2013; 110: 205-212 
[PMID: 23702623 DOI: 10.1160/th13-02-0150]
2 Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann 
F, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, 
Rasmussen LH, Siegbahn A, Storey RF, Weitz JI. Non-vitamin K 
antagonist oral anticoagulants (NOACs): No longer new or novel. 
Thromb Haemost 2014; 111: 781-782 [PMID: 24658395 DOI: 
10.1160/th14-03-0228]
3 Barnes GD, Ageno W, Ansell J, Kaatz S. Recommendation on the 
nomenclature for oral anticoagulants: communication from the 
SSC of the ISTH. J Thromb Haemost 2015; 13: 1154-1156 [PMID: 
25880598 DOI: 10.1111/jth.12969]
4 Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The 
metabolism and disposition of the oral direct thrombin inhibitor, 
dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399 
[PMID: 18006647 DOI: 10.1124/dmd.107.019083]
5 Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, 
Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated 
European Heart Rhythm Association Practical Guide on the use 
of non-vitamin K antagonist anticoagulants in patients with non-
valvular atrial fibrillation. Europace 2015; 17: 1467-1507 [PMID: 
26324838 DOI: 10.1093/europace/euv309]
6 Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, 
Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser 
SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FW, Veltkamp 
R, Lip GY. Choosing a particular oral anticoagulant and dose for 
Cheung KS et al . GI bleeding in patients on NOACs
1961 March 21, 2017|Volume 23|Issue 11|WJG|www.wjgnet.com
stroke prevention in individual patients with non-valvular atrial 
fibrillation: part 2. Eur Heart J 2016; Epub ahead of print [PMID: 
26848150 DOI: 10.1093/eurheartj/ehw069]
7 Kreutz R. Pharmacodynamic and pharmacokinetic basics of 
rivaroxaban. Fundam Clin Pharmacol 2012; 26: 27-32 [PMID: 
21848931 DOI: 10.1111/j.1472-8206.2011.00981.x]
8 Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study 
of the pharmacokinetics and pharmacodynamics of rivaroxaban in 
healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765 
[PMID: 18715524 DOI: 10.1185/03007990802361499]
9 Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, 
Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban 
metabolism and pharmacokinetics after oral administration to 
humans. Drug Metab Dispos 2009; 37: 74-81 [PMID: 18832478 
DOI: 10.1124/dmd.108.023143]
10 Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants 
in gastroenterology practice. Gastrointest Endosc 2013; 78: 227-239 
[PMID: 23725876 DOI: 10.1016/j.gie.2013.04.179]
11 Lim YJ, Yang CH. Non-steroidal anti-inflammatory drug-induced 
enteropathy. Clin Endosc 2012; 45: 138-144 [PMID: 22866254 
DOI: 10.5946/ce.2012.45.2.138]
12 Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey 
JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener 
HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of 
bleeding with 2 doses of dabigatran compared with warfarin in 
older and younger patients with atrial fibrillation: an analysis of the 
randomized evaluation of long-term anticoagulant therapy (RE-LY) 
trial. Circulation 2011; 123: 2363-2372 [PMID: 21576658 DOI: 
10.1161/circulationaha.110.004747]
13 Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, 
Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, 
Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox 
KA. Management of major bleeding events in patients treated with 
rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur 
Heart J 2014; 35: 1873-1880 [PMID: 24658769 DOI: 10.1093/
eurheartj/ehu083]
14 Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott 
SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, 
Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel 
SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus 
warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 
2093-2104 [PMID: 24251359 DOI: 10.1056/NEJMoa1310907]
15 Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, 
Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige 
Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, Bleeding, and 
Mortality Risks in Elderly Medicare Beneficiaries Treated With 
Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. 
JAMA Intern Med 2016; 176: 1662-1671 [PMID: 27695821 DOI: 
10.1001/jamainternmed.2016.5954]
16 Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral 
anticoagulants increase risk for gastrointestinal bleeding: a 
systematic review and meta-analysis. Gastroenterology 2013; 145: 
105-112.e15 [PMID: 23470618 DOI: 10.1053/j.gastro.2013.02.041]
17 Cannon CP, Kohli P. Danger ahead: watch out for indirect 
comparisons! J Am Coll Cardiol 2012; 60: 747-748 [PMID: 
22898071 DOI: 10.1016/j.jacc.2012.05.012]
18 Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, 
Schulman S, Ortel TL, Pauker SG, Colwell CW. Prevention of 
VTE in orthopedic surgery patients: Antithrombotic Therapy 
and Prevention of Thrombosis, 9th ed: American College of 
Chest Physicians Evidence-Based Clinical Practice Guidelines. 
Chest 2012; 141: e278S-e325S [PMID: 22315265 DOI: 10.1378/
chest.11-2404]
19 He Y, Wong IC, Li X, Anand S, Leung WK, Siu CW, Chan 
EW. The association between non-vitamin K antagonist oral 
anticoagulants and gastrointestinal bleeding: a meta-analysis of 
observational studies. Br J Clin Pharmacol 2016; 82: 285-300 
[PMID: 26889922 DOI: 10.1111/bcp.12911]
20 Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, 
Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, 
Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener 
HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in 
patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 
[PMID: 19717844 DOI: 10.1056/NEJMoa0905561]
21 Yavuz B, Ayturk M, Ozkan S, Ozturk M, Topaloglu C, Aksoy 
H, Şabanoglu C, Tanalp AC, Dal K, Ata N, Yavuz BB. A real 
world data of dabigatran etexilate: multicenter registry of oral 
anticoagulants in nonvalvular atrial fibrillation. J Thromb 
Thrombolysis 2016; 42: 399-404 [PMID: 27085540 DOI: 10.1007/
s11239-016-1361-4]
22 Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, 
Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate 
and warfarin in “real-world” patients with atrial fibrillation: a 
prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 
2264-2273 [PMID: 23562920 DOI: 10.1016/j.jacc.2013.03.020]
23 Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The 
impact of bleeding complications in patients receiving target-
specific oral anticoagulants: a systematic review and meta-analysis. 
Blood 2014; 124: 2450-2458 [PMID: 25150296 DOI: 10.1182/
blood-2014-07-590323]
24 Senoo K, Lau YC, Dzeshka M, Lane D, Okumura K, Lip GY. 
Efficacy and safety of non-vitamin K antagonist oral anticoagulants 
vs. warfarin in Japanese patients with atrial fibrillation - meta-
analysis. Circ J 2015; 79: 339-345 [PMID: 25501801 DOI: 
10.1253/circj.CJ-14-1042]
25 Rong F, Jia B, Huang P, Lynn HS, Zhang W. Safety of the direct-
acting anticoagulants in patients with atrial fibrillation: a meta-
analysis. Thromb Res 2015; 135: 1117-1123 [PMID: 25891842 
DOI: 10.1016/j.thromres.2015.04.004]
26 Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu 
N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, 
Yamashita T, Antman EM. Comparison of the efficacy and safety 
of new oral anticoagulants with warfarin in patients with atrial 
fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 
955-962 [PMID: 24315724 DOI: 10.1016/s0140-6736(13)62343-0]
27 Loffredo L, Perri L, Violi F. Impact of new oral anticoagulants 
on gastrointestinal bleeding in atrial fibrillation: A meta-analysis 
of interventional trials. Dig Liver Dis 2015; 47: 429-431 [PMID: 
25732432 DOI: 10.1016/j.dld.2015.01.159]
28 Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. 
Meta-analysis of efficacy and safety of new oral anticoagulants 
(dabigatran, rivaroxaban, apixaban) versus warfarin in patients 
with atrial fibrillation. Am J Cardiol 2012; 110: 453-460 [PMID: 
22537354 DOI: 10.1016/j.amjcard.2012.03.049]
29 Caldeira D, Barra M, Ferreira A, Rocha A, Augusto A, Pinto FJ, 
Costa J, Ferreira JJ. Systematic review with meta-analysis: the risk 
of major gastrointestinal bleeding with non-vitamin K antagonist 
oral anticoagulants. Aliment Pharmacol Ther 2015; 42: 1239-1249 
[PMID: 26434935 DOI: 10.1111/apt.13412]
30 Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, 
Rosendaal FR. Bleeding in patients receiving vitamin K antagonists 
who would have been excluded from trials on which the indication 
for anticoagulation was based. Blood 2008; 111: 4471-4476 [PMID: 
18316627 DOI: 10.1182/blood-2007-11-123711]
31 Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke 
W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker 
RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. 
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N 
Engl J Med 2011; 365: 883-891 [PMID: 21830957 DOI: 10.1056/
NEJMoa1009638]
32 Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, 
Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, 
Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes 
M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser 
SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon 
JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. 
Apixaban versus warfarin in patients with atrial fibrillation. N 
Engl J Med 2011; 365: 981-992 [PMID: 21870978 DOI: 10.1056/
NEJMoa1107039]
33 Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, 
Cheung KS et al . GI bleeding in patients on NOACs
1962 March 21, 2017|Volume 23|Issue 11|WJG|www.wjgnet.com
Cram P. Bleeding rates in Veterans Affairs patients with atrial 
fibrillation who switch from warfarin to dabigatran. Am J 
Med 2014; 127: 1179-1185 [PMID: 25107386 DOI: 10.1016/
j.amjmed.2014.07.024]
34 Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown 
W, Shah ND. Comparative risk of gastrointestinal bleeding with 
dabigatran, rivaroxaban, and warfarin: population based cohort 
study. BMJ 2015; 350: h1857 [PMID: 25910928 DOI: 10.1136/
bmj.h1857]
35 Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. 
Dabigatran and rivaroxaban use in atrial fibrillation patients on 
hemodialysis. Circulation 2015; 131: 972-979 [PMID: 25595139 
DOI: 10.1161/circulationaha.114.014113]
36 Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of 
gastrointestinal bleeding associated with oral anticoagulants: 
population based retrospective cohort study. BMJ 2015; 350: h1585 
[PMID: 25911526 DOI: 10.1136/bmj.h1585]
37 Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart 
MA, Fang G. Effectiveness and safety of dabigatran and warfarin 
in real-world US patients with non-valvular atrial fibrillation: a 
retrospective cohort study. J Am Heart Assoc 2015; 4: pii: e001798 
[PMID: 25862791 DOI: 10.1161/jaha.115.001798]
38 Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong 
IC. Prevention of Dabigatran-Related Gastrointestinal Bleeding 
With Gastroprotective Agents: A Population-Based Study. 
Gastroenterology 2015; 149: 586-595.e3 [PMID: 25960019 DOI: 
10.1053/j.gastro.2015.05.002]
39 Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, 
Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini 
JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA. Efficacy and 
safety of rivaroxaban compared with warfarin among elderly 
patients with nonvalvular atrial fibrillation in the Rivaroxaban Once 
Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin 
K Antagonism for Prevention of Stroke and Embolism Trial in 
Atrial Fibrillation (ROCKET AF). Circulation 2014; 130: 138-146 
[PMID: 24895454 DOI: 10.1161/circulationaha.113.005008]
40 Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, 
Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, 
Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with 
dabigatran or warfarin in the Randomized Evaluation of Long-Term 
Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127: 
634-640 [PMID: 23271794 DOI: 10.1161/circulationaha.112.115386]
41 Southworth MR, Reichman ME, Unger EF. Dabigatran and 
postmarketing reports of bleeding. N Engl J Med 2013; 368: 
1272-1274 [PMID: 23484796 DOI: 10.1056/NEJMp1302834]
42 Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier 
D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, 
Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin 
L, Yusuf S. Dabigatran versus warfarin: effects on ischemic and 
hemorrhagic strokes and bleeding in Asians and non-Asians with 
atrial fibrillation. Stroke 2013; 44: 1891-1896 [PMID: 23743976 
DOI: 10.1161/strokeaha.113.000990]
43 Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor 
V-Leiden mutation in four distinct American ethnic populations. 
Am J Med Genet 1997; 73: 334-336 [PMID: 9415695]
44 Kujovich JL. Factor V Leiden thrombophilia. Genet Med 2011; 
13: 1-16 [PMID: 21116184 DOI: 10.1097/GIM.0b013e3181faa0f2]
45 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. 
A novel user-friendly score (HAS-BLED) to assess 1-year risk of 
major bleeding in patients with atrial fibrillation: the Euro Heart 
Survey. Chest 2010; 138: 1093-1100 [PMID: 20299623 DOI: 
10.1378/chest.10-0134]
46 Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation 
of a novel risk score for predicting bleeding risk in anticoagulated 
patients with atrial fibrillation: the HAS-BLED (Hypertension, 
Abnormal Renal/Liver Function, Stroke, Bleeding History or 
Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) 
score. J Am Coll Cardiol 2011; 57: 173-180 [PMID: 21111555 
DOI: 10.1016/j.jacc.2010.09.024]
47 Abraham NS, Castillo DL. Novel anticoagulants: bleeding risk and 
management strategies. Curr Opin Gastroenterol 2013; 29: 676-683 
[PMID: 24100724 DOI: 10.1097/MOG.0b013e328365d415]
48 Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral 
thrombin inhibitor. Circulation 2011; 123: 1436-1450 [PMID: 
21464059 DOI: 10.1161/circulationaha.110.004424]
49 Weitz JI, Pollack CV. Practical management of bleeding in 
patients receiving non-vitamin K antagonist oral anticoagulants. 
Thromb Haemost 2015; 114: 1113-1126 [PMID: 26155974 DOI: 
10.1160/th15-03-0222]
50 Lip GY, Lane DA. Matching the NOAC to the Patient: Remember 
the Modifiable Bleeding Risk Factors. J Am Coll Cardiol 2015; 66: 
2282-2284 [PMID: 26610875 DOI: 10.1016/j.jacc.2015.07.086]
51 Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist 
oral anticoagulants (NOACs) for stroke prevention in Asian 
patients with atrial fibrillation: time for a reappraisal. Int J 
Cardiol 2015; 180: 246-254 [PMID: 25463377 DOI: 10.1016/
j.ijcard.2014.11.182]
52 Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, 
Lip GY. Anticoagulant-related gastrointestinal bleeding--could this 
facilitate early detection of benign or malignant gastrointestinal 
lesions? Ann Med 2014; 46: 672-678 [PMID: 25174259 DOI: 
10.3109/07853890.2014.952327]
53 van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, 
Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, 
oral direct thrombin inhibitor: interpretation of coagulation assays 
and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 
1116-1127 [PMID: 20352166 DOI: 10.1160/th09-11-0758]
54 Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti 
V, Slowinski T, Neumayer HH, Liesenfeld KH, Lehr T, Härtter 
S, Friedman J, Peters H, Clemens A. Effective elimination of 
dabigatran by haemodialysis. A phase I single-centre study in 
patients with end-stage renal disease. Thromb Haemost 2013; 109: 
596-605 [PMID: 23389759 DOI: 10.1160/th12-08-0573]
55 Dusel CH, Grundmann C, Eich S, Seitz R, König H. Identification 
of prothrombin as a major thrombogenic agent in prothrombin 
complex concentrates. Blood Coagul Fibrinolysis 2004; 15: 
405-411 [PMID: 15205589]
56 Wong H, Keeling D. Activated prothrombin complex concentrate 
for the prevention of dabigatran-associated bleeding. Br J 
Haematol 2014; 166: 152-153 [PMID: 24617554 DOI: 10.1111/
bjh.12831]
57 Htun KT, McFadyen J, Tran HA. The successful management of 
dabigatran-associated critical end-organ bleeding with recombinant 
factor VIIa. Ann Hematol 2014; 93: 1785-1786 [PMID: 24584995 
DOI: 10.1007/s00277-014-2039-7]
58 Milling TJ, Refaai MA, Sarode R, Lewis B, Mangione A, Durn 
BL, Harman A, Lee ML, Goldstein JN. Safety of a Four-factor 
Prothrombin Complex Concentrate Versus Plasma for Vitamin 
K Antagonist Reversal: An Integrated Analysis of Two Phase 
IIIb Clinical Trials. Acad Emerg Med 2016; 23: 466-475 [PMID: 
26822172 DOI: 10.1111/acem.12911]
59 Masotti L, Lorenzini G, Seravalle C, Panigada G, Landini G, 
Cappelli R, Schulman S. Management of new oral anticoagulants 
related life threatening or major bleedings in real life: a brief report. 
J Thromb Thrombolysis 2015; 39: 427-433 [PMID: 25048833 
DOI: 10.1007/s11239-014-1112-3]
60 Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, 
Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen 
PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang 
B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N 
Engl J Med 2015; 373: 511-520 [PMID: 26095746 DOI: 10.1056/
NEJMoa1502000]
61 Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte 
JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt 
J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, 
Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, 
Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet 
Alfa for Acute Major Bleeding Associated with Factor Xa 
Inhibitors. N Engl J Med 2016; 375: 1131-1141 [PMID: 27573206 
DOI: 10.1056/NEJMoa1607887]
Cheung KS et al . GI bleeding in patients on NOACs
1963 March 21, 2017|Volume 23|Issue 11|WJG|www.wjgnet.com
62 Abo-Salem E, Becker RC. Reversal of novel oral anticoagulants. 
Curr Opin Pharmacol 2016; 27: 86-91 [PMID: 26939028 DOI: 
10.1016/j.coph.2016.02.008]
63 Hwang JH, Fisher DA, Ben-Menachem T, Chandrasekhara V, 
Chathadi K, Decker GA, Early DS, Evans JA, Fanelli RD, Foley 
K, Fukami N, Jain R, Jue TL, Khan KM, Lightdale J, Malpas PM, 
Maple JT, Pasha S, Saltzman J, Sharaf R, Shergill AK, Dominitz 
JA, Cash BD. The role of endoscopy in the management of acute 
non-variceal upper GI bleeding. Gastrointest Endosc 2012; 75: 
1132-1138 [PMID: 22624808 DOI: 10.1016/j.gie.2012.02.033]
P- Reviewer: Aday AW, Barco S, Koizume S    S- Editor: Yu J 
L- Editor: A    E- Editor: Zhang FF
Cheung KS et al . GI bleeding in patients on NOACs
                                      © 2017 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
1   1
